The main established prebiotics and their beneficial/adverse intakes.
The human large intesine is inhabited by a diverse and complex bacterial flora, which includes an outstanding total number of 1014 cells, >1000 species and a biomass of more than 1 kg [1, 2]. Thus, the gut microbiota may be conceived as a specialized 'microbial organ' within the gut, affecting human health and disease through its involvement in pathogenesis, nutrition and immunity of the host [1-3]. Recently it has also been recognized that this dynamic yet stable ecosystem plays a role in conditions such as obesity and diabetes as well as in general well-being, from infancy to ageing [1-8]. Consequently, an increasing number of studies which explore the potential of promoting health by nutrition focuses on possible ways to influence and modulate the composition and activity of the gut flora towards a healthier one [4, 9-12].
In this respect, three major dietary approaches have been studied and applied. The first approach of probiotics is to fortify the gut flora through the consumption of exogenous live microorganisms, e.g.
Over the years, much attention has been drawn to indigestible carbohydrates that evade enzymatic digestion in the upper gastrointestinal tract and become available for fermentation in the colon . These dietary compounds were later termed as prebiotics, a definition of which has been updated into its current form as "a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microflora that confers benefits upon host well-being and health" [14, 15]. Although a more recent development compared to probiotics, prebiotics have been at the heart of various studies and numerous commercial products since they do not share the problem of probiotic survival upon ingestion by the consumer, and they can be added to a broad range of food products (e.g. confectionary and baked foods as well as more traditional fermented milk products and fruit drinks) because the majority of prebiotics are carbohydrates .
Amongst the carbohydrates currently marketed as prebiotics, inulin, fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS) and lactulose are consistently supported by high quality data from
2. Prebiotics as gut flora management tools
2.1. Established prebiotics
Overall, three major groups of compounds have been consistently established as prebiotics conferring health benefits (as detailed in Table 1): fructans, which include inulin and fructo-oligosaccharides (FOS), galacto-oligosaccharides and lactulose. Under the general term fructans one can classify three established prebiotic carbohydrates: inulin, fructo-oligosaccharides (FOS) and short chain fructo-oligosaccharides (scFOS) [16-18]. The fructans are polymers composed of D-fructose units joined by β-2-1 glycosidic linkages and terminated by an α-1-2-linked D-glucose.
|5-15||Stimulate bifidobacteria growth|
Production of short chain fatty acids
Protection against enteric infections
|"/> 15 (increase in fecal output)|||
|10-15||"/> 15 (increase in fecal output)|||
|10-15||"/> 20 g/human body (diarrhea)|||
|10||"/> 20 (laxative)|||
The degree of polymerization (DP), defined by the number of monosaccharide units, is used to distinguish between inulin, FOS and scFOS. Molecules with a DP between 2-60 are referred to as inulin. Inulin is commercially produced from chicory roots, but it is present in varying extent also in onions, garlic, Jerusalem artichoke, tomato and banana [11, 16, 21]. Similarly, oligofructose, commonly referred to as FOS, is prepared from chicory in an enzymatic hydrolysis using inulinase, and defined as oligosaccharide fractions which have a maximal DP of 20 with most common commercial products having an average DP of 9. In contrast, scFOS are synthesized in an enzymatic reaction via transfer of fructosyl units from sucrose molecules to yield mixtures of fructosyl chains with a maximum DP of 5. The mixture produced is usually comprised mainly of 1-kestose (2 units of fructose linked to glucose, GF2), nystose (GF3) and 1-fructosyl nystose (GF4) [16, 17, 24].
Fructans have a long tradition as prebiotics. Since their fructose units are joined by β-linkages, they are resistant to hydrolysis by the human digestive enzymes which mainly cleave α-linkages. As a consequence, when these carbohydrates reach the colon they selectively stimulate the growth of beneficial bacteria such as bifidobacteria, which do contain specific enzymes for their degradation, i.e. β-fructosidases [16, 21, 25]. Therefore, inulin, FOS and scFOS are classified as 'nondigestible' carbohydrates, with a calorie value of 1.5-2.0 kcal/g . FOS fermentation in the colon results in increased levels of short chain fatty acids (SCFA) which lower the pH in the intestinal lumen. This can provide an explanation to the reports that these fructans lead to a decrease in the number of harmful bacteria in the colon (such as
Galacto-oligosaccharides (GOS) are galactose-containing oligosaccharide mixtures of the form Glu α-1-4[β-Gal-1-6]n where n can be between two to five. They are produced from lactose syrup using β-galactosidases, which catalyze the hydrolysis of lactose into glucose and galactose, and also the transgalactosylation reactions with lactose as acceptor of galactose units giving rise to a variety of glycosidic linkages and molecular weights [11, 16, 19, 21]. Furthermore, the use of different enzymes in the various production processes of GOS leads to variability in their purity and glycosidic linkages, with β-1-6, β-1-3 and β-1-4 being the dominant . Several
Most of the health effects related to GOS arise from their selective fermentation by bifidobacteria and lactobacilli. In fact, it has been reported that when added to infant milk formulas, these oligosaccharides replicated the bifidogenic effect of human breast milk, not only in bacterial counts, but also with respect to the metabolic activity of the microflora in the colon [16, 27]. The growth of
Finally, lactulose (β-1-4-galactosyl-fructose) is a synthetic disaccharide derived from lactose. It is commonly used as a laxative in pharmaceutical products for the treatment of constipation, in doses over 20 g/day [16, 21]. Nevertheless, human trials have shown that at lower doses, lactulose acts as a prebiotic, reaching the colon and increasing bifidobacteria counts [2, 16, 17, 23]. Although this substance is an established prebiotic, it is still heavily confined to applications as a therapeutic agent.
2.2. Novel prebiotics
The search for new and novel prebiotics is constantly driven by the increased interest in management of human health through nutrition, particularly by the modulation of gut flora. In addition, studies of established prebiotics have enabled the better understanding of mechanisms of action and properties, which provided the basis for emerging prebiotics. Among the large array of prebiotic candidates, isomalto-oligosaccharides (IMO), xylo-oligosaccharides (XOS), soy-oligosaccharides (SOS), gluco-oligosaccharides, lactosucrose and resistant starches can be classified as emerging prebiotics [17, 33-40]. Some of these compounds present advantages over established prebiotics; for example, XOS are stable across a wide range of pH, hence they are resistant to degradation in low pH juices, in contrast to inulin . Besides attempts to identify and isolate naturally occurring prebiotics there are also attempts to enhance and extend the functionality of exisiting natural prebiotics through a rational design approach .
Promising results have been reported, including the selective growth of bifidobacteria and lactobacilli and/or the formation of beneficial metabolites, such as short chain fatty acids. However, it should be noted that these studies are still limited to
3. Efficacy of prebiotics across the life span
3.1. Methods to evaluate prebiotics
Research into the efficacy of prebiotics includes a collection of methods currently in use, from pure cultures to human trials, which can be generally classified into
In spite of their high significance,
One of the first
3.2. Prebiotic efficacy in infancy and childhood
At birth, the neonate gut is considered to be sterile with rapid colonization by bacteria believed to occur in three phases: delivery, breastfeeding and weaning to solid foods [52-54]. Immediately after birth, facultative anaerobic bacteria such as
The interest in prebiotics as a nutritional strategy to program infant gut microbiota to favor a more advantageous population has been inspired by the beneficial effects attributed to the 200 different human milk oligosaccharides (HMO) [52-54]. Based on the observations of bifidobacteria in the feces of breastfed babies, attempts have been made to reproduce this bifidogenic aspect in infant formulas by adding commercial prebiotics, in particular FOS and GOS [8, 53]. This practical application of prebiotics was evaluated for example in double-blind, randomized and controlled studies in 90 full term infants, which demonstrated that 4 g/L or 8 g/L of FOS, GOS or their combination resulted in a significant decrease in fecal pH and a concomitant increase in bifidobacteria and lactobacilli after 28 days feeding [61, 62]. A GOS and FOS mixture at a ratio of 9:1 (GOS:FOS) has been extensively studied as a prebiotic additive to infant formulas , and shown to increase bifidobacteria in infant feces and lower the incidence of pathogens [64-66]. Therefore, the administration of FOS and GOS into commercial infant formulas for their prebiotic effects has spread, and researchers continue exploring additional prebiotics as possible candidates for infant formulas supplementation. Moreover, studies are also looking into the persistence of the prebiotic effects.
3.3. Prebiotic efficacy in adulthood
To date, various studies have determined fructans (inulin and FOS) induce different beneficial effects on the health and general well-being of healthy adult subjects [10, 16-18]. A daily consumption of 5-10 g of fructans has been demonstrated to exert a bifidogenic effect on healthy adults based on dose-response studies, while similar doses of GOS and lactulose have been reported in
Additionally, established prebiotics have been linked to protection against enteric infections, modification of the host immune response, production of short chain fatty acids, particularly butyrate, increased mineral absorption and even the reduced risk of colon cancer [10, 11, 14, 16, 18]. Prebiotics efficacy has also been studied during pregnancy and lactation. These life periods are sometimes accompanied by irregular gastrointestinal activity, which can be improved by the consumption of dietary fibers and prebiotics . Furthermore, gestational weight gain and postpartum weight retention have been suggested to be affected from prebiotics intake, since they modulate the gut microflora . However, it is also important to note that the prebiotic effect has not been found to extend to neonates and infants, even when solely breast fed.
3.4. Prebiotics efficacy in ageing
At the old age, increased threshold for taste and smell as well as masticatory dysfunction can lead to a nutritionally imbalanced diet. In addition, various physiological functions deteriorate with age and may influence the absorption and/or metabolism of nutrients. Furthermore, the increased intake of drugs results in GI disturbances due to antibiotics undesired effect on indigenous bacteria in the host gut flora. Thus, changes in the GI tract, modification of diet and host immune system inevitably give rise to bacterial population alterations [70, 71]. In spite of the increasing proportion of the elderly in Western countries [72, 73], scarce data exists on the changes that occur in the intestinal microbiota during the ageing process and their possible health outcomes. Overall, an increase in facultative anaerobes and decrease in
Therefore, modulation of the colon microflora by the consumption of prebiotics is increasingly being studied as a potent, cost effective and natural way to improve the health and well-being of elderly people as well as reduce risks for various diseases [70, 71, 74]. FOS and GOS ingestion, as well as synbiotic preparations, were found to significantly increase the number of bifidobacteria at the expense of less beneficial microbiota in ageing individuals [6, 75-78]. In addition, a randomized, double-blind, controlled study with 74 subjects aged 70 and over has indicated that prebiotic addition can improve the low noise inflammatory process frequently observed in this sensitive population .
4. Prebiotics as therapeutics
4.1. Prebiotics therapeutic efficacy in human diseases
It is now well documented that the bacteria microflora residing in the human GI has a role not only in promoting health but also in preventing some diseases [3, 80, 81]. Prebiotics have been reported to protect against pathogenic gastrointestinal infections by promoting the growth of probiotics which help displace pathogens from the mucosa, producing antimicrobial agents and competing with pathogens on binding sites and nutrients . In addition to
Prebiotics have also been reported to reduce the risk of colon cancer as a result of gut flora modulation [11, 14, 16-18]. Specifically, they support the metabolism of carcinogenic molecules and the secretion of short chain fatty acids to the lumen by the colon microbiota [83, 84]. Furthermore, human trials have demonstrated that inulin, FOS and scFOS beneficially affect colorectal cell proliferation and genotoxicity , hence the potential of prebiotics in prevention and treatment of colon cancer should be further explored.
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), has also been researched as a possible target for prebiotics [11, 16, 17]. As mucosal communities significantly change in these diseases, prebiotics may be used in order to manipulate them. For example, patients fed 15 g per day of a prebiotic mixture composed of 7.5 g inulin and 7.5 g FOS for 2 weeks prior to colonoscopy, have had more than a 10-fold increase in bifidobacterial and eubacterial numbers in the mucosa of the proximal and distal colon . Similarly, in a small open-label human trial, 10 patients with active ileum-colonic CD were fed 15 g FOS daily for 3 weeks, after which a significant reduction in the Harvey Bradshaw index of disease activity was observed as well as an increase of fecal bifidobacteria numbers .
4.2. Prospective therapeutic targets
4.2.1. Obesity and the metabolic syndrome
Increasing evidence linking gut flora to human health and diseases have inspired further research regarding the possible link between gut flora and obesity, which has led to the notion that prebiotics could be harnessed as potential therapeutic agents or management tools to prevent and treat obesity and the metabolic syndrome [4, 5, 7, 20, 52]. The metabolic syndrome is a cluster of metabolic abnormalities, including abdominal obesity, type 2 diabetes mellitus and cardiovascular diseases [86, 87].
Various studies have shown that prebiotic intervention decreased fat storage in white adipose tissues and in the liver, decreased hepatic insulin resistance as well as systemic inflammation in several nutritional (high-fat diet-fed) and genetic (
However, to date, the mechanisms underlying the complex role of gut microbiota in such conditions are largely unknown . It has been reported that a lower number of bifidobacteria at birth is associated with overweight later in childhood , and in adults, the number of bifidobacteria is slightly lower in individuals with obesity than in lean subjects . The number of these bacteria is also decreased in patients with type 2 diabetes mellitus compared with nondiabetic people . Hence, these results seem to suggest that bifidobacteria affects the development of obesity and its related comorbidities .
A remarkable increase has been observed in the number of
A pathway involving short chain fatty acids (SCFA) has been proposed to be involved in the interplay between prebiotics, the gut flora and obesity. SCFA act as signaling molecules and are specific ligands for at least two G protein-coupled receptors, GPR41 and GPR43, which have a potential role in fat mass development [13, 104]. In addition, it has been shown that acetate and propionate can modify hepatic lipid metabolism . Interestingly, a recent study has demonstrated that diet-induced obesity and insulin resistance were prevented when mice on a high-fat diet were supplemented with butyrate, which promoted energy expenditure and induced mitochondrial function . Various studies have shown that a diet enriched with prebiotics leads to a greater intestinal SCFA production and thereby migitates body weight gain, fat mass development and the severity of diabetes [89, 90, 100, 107-109]. Numerous peptides secreted by the enteroendocrine cells along the GI are involved in the regulation of energy homeostasis and/or pancreatic function. Three such peptides which can modulate food intake and energy expenditure are glucagon-like peptide-1 (GLP-1), peptide YY (PYY) and ghrelin [110-113]. Thus, it has been suggested that SCFA are related to changes in the gut peptide secretion, namely increased production and secretion of GLP-1 and PYY and the reduction of ghrelin which induce metabolic effects [13, 114, 115]. Piche
5. Future challenges
5.1. Harmonization of methods to evaluate efficacy
To date, a plethora of studies have investigated the effects of prebiotics on human health and well-being, leading to the general realization prebiotics could serve as a possible method of therapeutic intervention. However, the majority of these studies cannot be compared due to the variety of methods employed. For example, results obtained by bacterial isolation techniques [39, 119] cannot be compared with data from more advanced methods for the molecular characterization of the microbiota, now considered essential to obtain a comprehensive view of the gut ecosystem. Furthermore, DNA-based techniques including the use of the 16s ribosomal RNA gene are considered as less biased, hence their results are more reliable . In addition, studies focused on the effect of prebiotics on the elderly, even in healthy subjects, lack a clear definition of 'elderly', and various groups are recruited, usually on the basis of 'over 60' , 'over 65' [119, 121] or 'over 70' . This makes is difficult to define a 'threshold age' at which the gut environment starts to be influenced from the ageing process . Thus, harmonization of methods to evaluate efficacy is a prequisite step limiting the further application of prebiotics for the prevention and treatment of diseases as well as the development of novel prebiotics.
5.2. The challenge of personalization
A broad range of parameters has been known to affect the bacterial composition of the infant gut, e.g. mode of delivery, type of feeding (exclusive breastfeeding versus formula), antibiotic use and maternal infection [55-57, 123, 124]. Furthermore, various studies have indicated that the low number of certain bacteria at birth such as bifidobacteria is related to overweight later in childhood . Consequently, prebiotics supplementation even in infants may be used as a preventive nutritional programming tool, which will affect the health and well-being also in adulthood. Moreover, it has been increasingly accepted that environmental factors such as nutritional habits and lifestyle may impact the gut microbiota composition, for example striking country-related differences in the effects of age on the microflora have been reported . This wide variety of factors, affecting intestinal microbiota composition from infancy to elderly, drove the need for personalized nutrition, including personalized and tailored prebiotics. In addition, since prebiotics are recently considered even as therapeutic agents for the prevention and treatment of diseases, it may be beneficial to aim personalized prebiotics to people at high-risk to develop these illnesses. Thus, the challenge of personalization includes performing long-term, large-sized, well-controlled and multidisciplinary-collaborated studies which will demonstrate and establish the health promoting effects of prebiotics and enable harnessing them in the clinic or in supermarket shelves.
Prebiotics have emerged as cost-effective and efficient nutritional programming tools to beneficially and selectively promote the growth and/or activity of certain bacteria in the indigenous flora of the human GI. So far, prebiotics have been demonstrated to exert various beneficial effects during an individual's lifetime, from infancy to ageing, as well as function as therapeutic agents for the prevention and treatment of different diseases, including obesity and the metabolic syndrome.
In addition to the well-established prebiotics of FOS, GOS and lactulose, novel prebiotics are constantly being developed. State of the art techniques,
Future challenges include the harmonization of methods of evaluating efficacy that will help focus research efforts and enable a more comprehensive understanding of prebiotic mechanisms of action and beneficial effects and how these can be modulated. Another important prospect is personalization, i.e. fitting tailored prebiotics to individual needs in order to nutritionally program and affect their health and well-being from infancy and into old and prosperous age.
Diamant, M., E.E. Blaak, and W.M. de Vos, Do Nutrient-Gut-Microbiota Interactions Play a Role in Human Obesity, Insulin Resistance and Type 2 Diabetes? Obesity Reviews, 2011 272 281
Venema, K., Intestinal Fermentation of Lactose and Prebiotic Lactose Derivatives, including Human Milk Oligosaccharides.
EMBO Rep, O’Hara A. M. Shanahan F. The Gut. as Flora a. Forgotten Organ. E. M. B. 2006 688 693
Delzenne, N.M. and P.D. Cani, Nutritional Modulation of Gut Microbiota in the Context of Obesity and Insulin Resistance: Potential Interest of Prebiotics.
Duncan, S.H., et al., Human Colonic Microbiota Associated with Diet, Obesity and Weight Loss.
Tuohy, K.M., Inulin-Type Fructans in Healthy Aging.
Nutritional Therapy and Metabolism, Tuohy K. M. Costabile A. Fava F. The Gut. Microbiota in. Obesity Metabolic-A Disease. Novel Therapeutic. Target 2009 113 133
Parracho, H., A.L. McCartney, and G.R. Gibson, Probiotics and Prebiotics in Infant Nutrition.Proceedings of the Nutrition Society, 2007 405 411
Fooks L. J. Fuller R. Gibson G. R. Prebiotics Probiotics. Human Gut. Microbiology
Gibson, G.R., Prebiotics as Gut Microflora Management Tools.
Macfarlane, S., G.T. Macfarlane, and J.H. Cummings, Review Article: Prebiotics in the Gastrointestinal Tract.
Tuohy, K.M., et al., Using Probiotics and Prebiotics to Improve Gut Health.
De Preter, V., et al., The Impact of Pre- and/or Probiotics on Human Colonic Metabolism: Does It Affect Human Health? Molecular Nutrition & Food Research, 2011 46 57
Gibson, G.R., From Probiotics to Prebiotics and a Healthy Digestive System.
The American Journal of Clinical Nutrition, Schrezenmeir J. de Vrese M. Probiotics Prebiotics. Synbiotics Approaching a. Definition 2001 361S 364S
Tuohy, K.M., et al., Modulation of the Human Gut Microflora Towards Improved Health Using Prebiotics- Assessment of Efficacy.Current Pharmaceutical Design, 2005 75 90
Annual Review of Food Science and Technology, Rastall R. A. Functional Oligosaccharides. Application Manufacture 2010 305 339
Sabater-Molina, M., et al., Dietary Fructooligosaccharides and Potential Benefits on Health.
Torres D. P. M. et al. Galacto-Oligosaccharides Production. Properties Applications. as Significance Prebiotics.
Champ M. Hoebler C. Functional Food. for Pregnant. Lactating Women. in Perinatal. Nutrition A. Role for. Dietary Fibres?. Current Opinion. in Clinical. Nutrition Metabolic Care. 2009 565 574
Caselato de Sousa, V.M., E.F. dos Santos, and V.C. Sgarbieri, The Importance of Prebiotics in FunctionalFoods and Clinical Practice. Food and Nutrition Sciences, 2011 133 144
Bosscher D. Van Loo J. Franck A. Inulin as Oligofructose Prebiotics. in the. Prevention of. Intestinal Infections. Diseases
Panesar P. S. Kumari S. Lactulose Production. Purification Potential Applications.
Flamm G. et al. Inulin as Oligofructose Dietary. Fiber A. Review of. the Evidence.
Van den Ende. W. Peshev D. De Gara L. Disease Prevention. by Natural. Antioxidants Prebiotics Acting. as Scavengers R. O. S. in the. Gastrointestinal Tract.
British Journal of Nutrition, Van Loo J. et al. Functional Food. Properties of. Non-Digestible Oligosaccharides. A. Consensus Report. from the. E. N. D. O. Project-C . D. G. X. I. I. A. I. R. I. I. T94-1095 1999 121 132
Knol, J., et al., Colon Microflora in Infants Fed Formula with Galacto- and Fructo-Oligosaccharides: More Like Breast-Fed Infants.
Gopal, P.K., P.A. Sullivan, and J.B. Smart, Utilisation of Galacto-Oligosaccharides as Selective Substrates for Growth by Lactic Acid Bacteria Including Bifidobacterium lactis DR10 and Lactobacillus rhamnosus DR20.
Kaplan H. Hutkins R. W. Fermentation of. Fructooligosaccharides by. Lactic Acid. Bacteria Bifidobacteria
Kaplan H. Hutkins R. W. Metabolism of. Fructooligosaccharides by. Lactobacillus paracasei. 119
Searle, L.E.J., et al., Purified Galactooligosaccharide, Derived from a Mixture Produced by the Enzymic Activity of Bifidobacterium bifidum, Reduces Salmonella enterica Serovar Typhimurium Adhesion and Invasion In Vitro and In Vivo.
Shoaf, K., et al., Prebiotic Galactooligosaccharides Reduce Adherence of Enteropathogenic Escherichia coli to Tissue Culture Cells.
Mountzouris, K.C., et al., Modeling of Oligodextran Production in an Ultrafiltration Stirred-Cell Membrane Reactor.
Rycroft C. E. et al. Comparative A. In Vitro. Evaluation of. the Fermentation. Properties of. Prebiotic Oligosaccharides.
Kaneko, T., et al., Effects of Isomaltooligosaccharides with Different Degrees of Polymerization on Human Fecal Bifidobacteria.
Microbial Ecology in Health and Disease, Saito Y. Takano T. Rowland I. Effects of. Soybean Oligosaccharides. on the. Human Gut. Microflora in. In Vitro. Culture 1992 105 110
Sharp R. Fishbain S. Macfarlane G. T. Effect of. Short-Chain Carbohydrates. on Human. Intestinal Bifidobacteria. Escherichia coli. In Vitro.
Hopkins, M.J., J.H. Cummings, and G.T. Macfarlane, Inter-Species Differences in Maximum Specific Growth Rates and Cell Yields of Bifidobacteria Cultured on Oligosaccharides and Other Simple Carbohydrate Sources.
Hopkins, M.J. and G.T. Macfarlane, Changes in Predominant Bacterial Populations in Human Faeces with Age and with Clostridium difficile Infection.
Starch- Starke, Fuentes-Zaragoza E. et al. Resistant Starch. as Prebiotic A. Review 2011 406 415
Hernandez-Hernandez, O., et al., Characterization of Galactooligosaccharides Derived from Lactulose.
Lesmes, U., et al., Effects of Resistant Starch Type III Polymorphs on Human Colon Microbiota and Short Chain Fatty Acids in Human Gut Models.
Hur, S.J., et al., In Vitro Human Digestion Models forFood Applications.
Kong F. Singh R. P. Human A. Gastric Simulator. . H. G. S. to Study. Food Digestion. in Human. Stomach
Macfarlane G. T. Macfarlane S. Models For. Intestinal Fermentation. Association between. Food Components. Delivery Systems. Bioavailability Functional Interactions. in the. Gut
Benshitrit, R.C., et al., Development of OralFood-Grade Delivery Systems: Current Knowledge and Future Challenges.
Molly, K., et al., Validation of the Simulator of the Human IntestinalMicrobial Ecosystem (SHIME) Reactor Using Microorganism-associated Activities.
De Boever P. Deplancke B. Verstraete W. Fermentation by. Gut Microbiota. Cultured in. a. Simulator of. the Human. Intestinal Microbial. Ecosystem Is. Improved by. Supplementing a. Soygerm Powder.
Gmeiner, M., et al., Influence of a Synbiotic Mixture consisting of Lactobacillus acidophilus 74-2 and a Fructooligosaccharide Preparation on the Microbial Ecology Sustained in a Simulation of the Human Intestinal Microbial Ecosystem (SHIME Reactor).
Atla Alternatives To Laboratory Animals, Minekus M. et al. Multicompartmental A. Dynamic-Controlled Computer. Model Simulating. the Stomach. Small Intestine. 1995 197 209
Macfarlane G. T. Macfarlane S. Gibson G. R. Validation of. a. Three-Stage Compound. Continuous Culture. System for. Investigating the. Effect of. Retention Time. on the. Ecology Metabolism of. Bacteria in. the Human. Colon
Delzenne, N.M., et al., Targeting Gut Microbiota in Obesity: Effects of Prebiotics and Probiotics.
Chichlowski, M., et al., The Influence of Milk Oligosaccharides on Microbiota of Infants: Opportunities for Formulas.
Marques, T.M., et al., Programming Infant Gut Microbiota: Influence of Dietary and Environmental Factors.
Morelli, L., Postnatal Development of Intestinal Microflora as Influenced by Infant Nutrition.
Acta Pædiatrica, Adlerberth I. Wold A. E. Establishment of. the Gut. Microbiota in. Western Infants. 2009 229 238
Penders, J., et al., Factors Influencing the Composition of the Intestinal Microbiota in Early Infancy.
Palmer, C., et al., Development of the Human Infant Intestinal Microbiota.PLoS Biol, 2007 e177
Harmsen, H.J.M., et al., Analysis of Intestinal Flora Development in Breast-Fed and Formula-Fed Infants by Using Molecular Identification and Detection Methods Journal of Pediatric Gastroenterology & Nutrition, 2000 61 67
Rubaltelli, F.F., et al., Intestinal Flora in Breast- and Bottle-Fed Infants.Journal of Pediatric Gastroenterology & Nutrition, 1998 186 191
Moro, G., et al., Dosage-Related Bifidogenic Effects of Galacto- and Fructooligosaccharides in Formula-Fed Term Infants.
Moro, G.E., et al., Effects of a New Mixture of Prebiotics on Faecal Flora and Stools in Term Infants.
Acta Paediatrca Supplement, Fanaro S. et al. Galacto-Oligosaccharides Long-Chain-Oligosaccharides Fructo. as Prebiotics in. Infant Formulas. A. Review 2005 22 26
Boehm, G., et al., Supplementation of a Bovine Milk Formula with an Oligosaccharide Mixture Increases Counts of Faecal Bifidobacteria in Preterm Infants.
Haarman M. Knol J. Quantitative-Time Real. Assays P. C. R. To Identify. Quantify Fecal. Bifidobacterium Species. in Infants. Receiving a. Prebiotic Infant. Formula
Knol, J., et al., Increase of Faecal Bifidobacteria due to Dietary Oligosaccharides Induces a Reduction of Clinically Relevant Pathogen Germs in the Faeces of Formula-Fed Preterm Infants.Acta Paediatrca Supplement, 2005 31 33
Bouhnik, Y., et al., Administration of Transgalacto-Oligosaccharides Increases Fecal Bifidobacteria and Modifies Colonic Fermentation Metabolism in Healthy Humans.
Scandinavian Journal of Gastroenterolgy Supplement, Salminen S. Salminen E. Lactulose Lactic. Acid Bacteria. Intestinal Microecology. Mucosal Protection. 1997 45 48
Den Hond. E. Geypens B. Ghoos Y. Effect of. High Performance. Chicory Inulin. on Constipation.
Biagi, E., et al., Ageing of the Human Metaorganism: The Microbial Counterpart.
Ageing. Tiihonen K. Ouwehand A. C. Rautonen N. Human Intestinal. Microbiota Healthy Ageing.
Cohen, J.E., Human Population: The Next Half Century.
Christensen K. et al. Ageing Populations. The Challenges. Ahead The. Lancet 2009 1196 1208
Woodmansey E. J. Intestinal Bacteria. Ageing
Guigoz, Y., et al., Effects of Oligosaccharide on the Faecal Flora and Non-Specific Immune System in Elderly People.
Bartosch, S., et al., Microbiological Effects of Consuming a Synbiotic Containing Bifidobacterium bifidum, Bifidobacterium lactis, and Oligofructose in Elderly Persons, Determined by Real-Time Polymerase Chain Reaction and Counting of Viable Bacteria.Clinical Infectious Diseases, 2005 28 37
Bouhnik, Y., et al., Four-Week Short Chain Fructo-Oligosaccharides Ingestion Leads to Increasing Fecal Bifidobacteria and Cholesterol Excretion in Healthy Elderly Volunteers.
Vulevic, J., et al., Modulation of the Fecal Microflora Profile and Immune Function by a Novel Trans-Galactooligosaccharide Mixture (B-GOS) in Healthy Elderly Volunteers.The
Schiffrin, E.J., et al., Systemic Inflammatory Markers in Older Persons: The Effect of Oral Nutritional Supplementation with Prebiotics.Journal of Nutrition Health & Aging, 2007 475 479
Fava, F., et al., The Gut Microbiota and Lipid Metabolism: Implications for Human Health and Coronary Heart Disease.
The Guarner F. J. Malagelada R. Gut Flora. in Health. Disease
Saavedra J. M. Tschernia A. Human Studies. with Probiotics. Prebiotics Clinical. Implications
Louis P. Flint H. J. Diversity Metabolism. Microbial Ecology. of-Producing Butyrate. Bacteria from. the Human. Large Intestine. F. E. M.
Mc Garr S. E. Ridlon J. M. Hylemon P. B. Diet Anaerobic. Bacterial Metabolism. Colon Cancer. A. Review of. the Literature.
Langlands, S.J., et al., Prebiotic Carbohydrates Modify the Mucosa Associated Microflora of the Human Large Bowel.
Hotamisligil, G.S., Inflammation and Endoplasmic Reticulum Stress in Obesity and Diabetes.
Shoelson, S.E. and A.B. Goldfine, Getting Away from Glucose: Fanning the Flames of Obesity-Induced Inflammation.
Cani, P.D. and N.M. Delzenne, Interplay Between Obesity and Associated Metabolic Disorders: New Insights into the Gut Microbiota.
Cani, P.D., et al., Improvement of Glucose Tolerance and Hepatic Insulin Sensitivity by Oligofructose Requires a Functional Glucagon-Like Peptide 1 Receptor.
Cani, P.D., et al., Oligofructose Promotes Satiety in Rats Fed a High-Fat Diet: Involvement of Glucagon-like Peptide-1.
Cani, P.D., et al., Changes in Gut Microbiota Control Inflammation in Obese Mice through a Mechanism involving GLP-2-Driven Improvement of Gut Permeability.
Daubioul, C., et al., Dietary Fructans, but Not Cellulose, Decrease Triglyceride Accumulation in the Liver of Obese Zucker fa/fa Rats.
Daubioul, C.A., et al., Dietary Oligofructose Lessens Hepatic Steatosis, but Does Not Prevent Hypertriglyceridemia in Obese Zucker Rats.
Delmee, E., et al., Relation between Colonic Proglucagon Expression and Metabolic Response to Oligofructose in High Fat Diet-Fed Mice.
Roberfroid M. et al. Prebiotic Effects. Metabolic Health Benefits.
Abrams, S.A., et al., Effect of Prebiotic Supplementation and Calcium Intake on Body Mass Index.
Maurer, A.D., et al., Changes in Satiety Hormones and Expression of Genes Involved in Glucose and Lipid Metabolism in Rats Weaned Onto Diets High in Fibre or Protein Reflect Susceptibility to Increased Fat Mass in Adulthood.
Maurer, A., et al., Consumption of Diets High in Prebiotic Fiber or Protein During Growth Influences the Response to a High Fat and Sucrose Diet in Adulthood in Rats.
Kalliomaki, M., et al., Early Differences in Fecal Microbiota Composition in Children May Predict Overweight.The
Cani P. D. Dewever C. Delzenne N. M. Inulin-Type Fructans. Modulate Gastrointestinal. Peptides Involved. in Appetite. Regulation . Glucagon-Like Peptide. Ghrelin in. Rats
Wu, X., et al., Molecular Characterisation of the Faecal Microbiota in Patients with Type II Diabetes.
Delzenne, N.M. and C.M. Williams, Prebiotics and Lipid Metabolism.Cuurent Opinion in Lipidology, 2002 61 67
Cani, P.D., et al., Metabolic Endotoxemia Initiates Obesity and Insulin Resistance.
Cani, P.D. and N.M. Delzenne, The Gut Microbiome as Therapeutic Target.
Wong, J.M.W., et al., Colonic Health: Fermentation and Short Chain Fatty Acids.
Gao, Z., et al., Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice.
Cani P. D. et al. Oligofructose Promotes. Satiety in. Healthy Human. A. Pilot Study.
Cani, P.D., et al., Gut Microbiota Fermentation of Prebiotics Increases Satietogenic and Incretin Gut Peptide Production with Consequences for Appetite Sensation and Glucose Response After a Meal.The
Whelan, K., et al., Appetite During Consumption of Enteral Formula as a Sole Source of Nutrition: The Effect of Supplementing Pea-Fibre and Fructo-Oligosaccharides.British Journal of Nutrition, 2006 350 356
International Journal of Obesity, Chaudhri O. B. Field B. C. T. Bloom S. R. Gastrointestinal Satiety. Signals 2008S7): S28 S31
Cowley, M.A., et al., The Distribution and Mechanism of Action of Ghrelin in the CNS Demonstrates a Novel Hypothalamic Circuit Regulating Energy Homeostasis.
Druce M. R. Small C. J. Bloom S. R. Minireview Gut. Peptides Regulating. Satiety
Wynne K. et al. Appetite Control. Journal of. Endocrinology 2005 291 318
Freeland K. R. Wilson C. Wolever T. M. Adaptation of. Colonic Fermentation. Glucagon-Like Peptide. Secretion with. Increased Wheat. Fibre Intake. for . Year in. Hyperinsulinaemic Human. Subjects
Freeland, K.R. and T.M. Wolever, Acute Effects of Intravenous and Rectal Acetate on Glucagon-Like Peptide-1, Peptide YY, Ghrelin, Adiponectin and Tumour Necrosis Factor-Alpha.
Piche, T., et al., Colonic Fermentation Influences Lower Esophageal Sphincter Function in Gastroesophageal Reflux Disease.
Parnell, J.A. and R.A. Reimer, Weight Loss During Oligofructose Supplementation is Associated with Decreased Ghrelin and Increased Peptide YY in Overweight and Obese Adults.The
Tarini J. Wolever T. M. S. The Fermentable. Fibre Inulin. Increases Postprandial. Serum-Chain Short. Fatty Acids. Reduces-Fatty Free. Acids Ghrelin in. Healthy Subjects.
Woodmansey, E.J., et al., Comparison of Compositions and Metabolic Activities of Fecal Microbiotas in Young Adults and in Antibiotic-Treated and Non-Antibiotic-Treated Elderly Subjects.
Mueller S. et al. Differences in. Fecal Microbiota. in Different. European Study. Populations in. Relation to. Age Gender. Country A. Cross-Sectional Study.
Claesson, M.J., et al., Comparative Analysis of Pyrosequencing and a Phylogenetic Microarray for Exploring Microbial Community Structures in the Human Distal Intestine.
Mariat, D., et al., The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age.
Reinhardt C. Reigstad C. S. Backhed F. Intestinal Microbiota. During Infancy. Its Implications. for Obesity.
Biasucci, G., et al., Cesarean Delivery May Affect the Early Biodiversity of Intestinal Bacteria.